Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 6Small Cell Lung Carcinoma 4Cholangiocarcinoma 4Stomach Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Thyroid Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Sarcoma 1Refractory Metastatic Digestive System Carcinoma 1Pulmonary Neuroendocrine Tumor 1Pancreatic Cancer Metastatic 1Osteosarcoma 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Locally Advanced Pancreatic Cancer 1Head and Neck Cancers - Salivary Gland 1Gallbladder Neoplasms 1Differentiated Thyroid Cancer 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1Breast Neoplasms 1Appendiceal Neoplasms 1Advanced Solid Tumors 1Advanced Pancreatic Cancer 1Advanced Non-Small Cell Lung Cancer 1

Interventions

toripalimab 1surufatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Refractory Metastatic Digestive System Carcinoma × surufatinib × Clear all
NCT05030246 2021-09-01

Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer

Peking University

Phase 2 Unknown
72 enrolled

Refractory Metastatic Digestive System Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡